Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Women
This article, published in Clinical Infectious Diseases, shares findings of a trial involving 319 human immunodeficiency virus (HIV)-1-infected women in the United States, Brazil, and South Africa. The trial aimed to determine the immunogenicity and safety of the quadrivalent human papillomavirus (HPV) vaccine, as women with HIV are disproportionately affected by HPV-related anogenital disease. The results determined that quadrivalent HPV vaccine was safe and immunogenic in HIV-infected women aged 13 to 45 years.
Author(s): Kojic EM, Kang M, Cespedes MS, et al.
Visit web page (English)
(Located at cid.oxfordjournals.org)
Citation: Kojic EM, Kang M, Cespedes MS, et al. Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Women. Clinical Infectious Diseases. 2014;59(1):127-135.